Positive Phase III results for Allergan and Gedeon Richter

17 January 2017

Ireland-headquartered Allergan (NYSE: AGN) and Hungarian pharmaceutical company Gedeon Richter (BPSE: RICHTER) have announced positive results from a Phase III trial into ulipristal acetate, a treatment against uterine fibroids.

The results come from the second of two Phase III clinical trials currently underway, evaluating safety and efficacy in women with abnormal bleeding due to the condition.

The USA-based study, which included 432 patients, is reported by the companies to have reinforced the safety and efficacy data found in an earlier trial, meeting all co-primary and secondary endpoints.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK